ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
Morepen Laboratories has invested Rs. 20 Crore via a rights issue in its wholly-owned subsidiary, Morepen RX Limited, to strengthen its capital base.
Morepen Laboratories' board recommended a final dividend of Rs. 0.20 per equity share for FY 2025-26. The record date for the dividend is September 19, 2026.
Morepen Laboratories Limited has re-appointed Sushil Suri as Executive Director for a 36-month term, effective October 20, 2026. The Board approved this management change.
Morepen Laboratories' Monitoring Agency Report for Q1 FY27 confirms usage of QIP proceeds. The company faces a GST show-cause notice of ₹117.94 crore.
Morepen Laboratories reported record Q1 FY27 revenue of Rs. 575.31 Crore, up 34% YoY. Net profit surged 394% to Rs. 56.35 Crore following CDMO commercialization.
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.
Morepen Laboratories Ltd reported revenue from operations of ₹570.1 Cr (+34.1% YoY) and net profit of ₹56.3 Cr (+393.9% YoY) for Q1 FY27.
Morepen Laboratories has scheduled a board meeting for August 4, 2026, to approve the financial results for the quarter ended June 30, 2026.
Morepen Laboratories' wholly owned subsidiary, Morepen Labs - FZCO, changed its name to Morepen Labs FZE following migration from IFZA to JAFZA, Dubai.